- Home
- PALI vs GLMD Comparison
PALI vs GLMD Comparison
Compare PALI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- GLMD
- Stock Information
- Founded
- PALI 1996
- GLMD 2000
- Country
- PALI United States
- GLMD Israel
- Employees
- PALI N/A
- GLMD N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- GLMD Health Care
- Exchange
- PALI Nasdaq
- GLMD Nasdaq
- Market Cap
- PALI 7.5M
- GLMD 7.5M
- IPO Year
- PALI N/A
- GLMD 2014
- Fundamental
- Price
- PALI $0.60
- GLMD $1.51
- Analyst Decision
- PALI Strong Buy
- GLMD Hold
- Analyst Count
- PALI 2
- GLMD 1
- Target Price
- PALI $12.00
- GLMD N/A
- AVG Volume (30 Days)
- PALI 542.3K
- GLMD 224.4K
- Earning Date
- PALI 11-11-2025
- GLMD 08-28-2025
- Dividend Yield
- PALI N/A
- GLMD N/A
- EPS Growth
- PALI N/A
- GLMD N/A
- EPS
- PALI N/A
- GLMD N/A
- Revenue
- PALI N/A
- GLMD N/A
- Revenue This Year
- PALI N/A
- GLMD N/A
- Revenue Next Year
- PALI N/A
- GLMD N/A
- P/E Ratio
- PALI N/A
- GLMD N/A
- Revenue Growth
- PALI N/A
- GLMD N/A
- 52 Week Low
- PALI $0.53
- GLMD $1.15
- 52 Week High
- PALI $4.32
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- PALI 37.11
- GLMD 53.20
- Support Level
- PALI $0.70
- GLMD $1.33
- Resistance Level
- PALI $0.69
- GLMD $1.63
- Average True Range (ATR)
- PALI 0.04
- GLMD 0.11
- MACD
- PALI -0.00
- GLMD 0.03
- Stochastic Oscillator
- PALI 30.91
- GLMD 69.23
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.